In the Realm of Psychoneuroimmunology: The Role of Celecoxib as an Add-On Treatment for Bipolar Mania.

Molecular Neuropsychiatry Pub Date : 2018-12-01 Epub Date: 2018-11-08 DOI:10.1159/000494700

Mohammed Al-Alawi, Hamed Al Sinawi, Roshe Rashid

{"title":"In the Realm of Psychoneuroimmunology: The Role of Celecoxib as an Add-On Treatment for Bipolar Mania.","authors":"Mohammed Al-Alawi, Hamed Al Sinawi, Roshe Rashid","doi":"10.1159/000494700","DOIUrl":null,"url":null,"abstract":"<p><p>Bipolar affective disorder (BPAD) is a chronic debilitating psychiatric illness seriously affecting the quality of patients' life. The available treatment is effective in about half of those suffering from the illness. The neurobiological basis of the disorder is not fully unraveled. With such lacunae, attempts have been made to decipher the underlying neuroimmunological process of the illness as is the case with other mental disorders. As a result, some inflammatory processes have been implicated in the etiology of BPAD, as described in this communication. Subsequently, the role of anti-inflammatory agents such as celecoxib was investigated by treating different phases of BPAD. Given the promising outcomes of several trials and reviews, celecoxib has gained momentum and has been recommended as an adjunctive treatment by some guidelines for treating resistant BPAD cases. This brief communication highlights some of the caveats in the randomized trials using celecoxib as an add-on treatment in bipolar mania specifically, which need to be addressed in future work.</p>","PeriodicalId":18957,"journal":{"name":"Molecular Neuropsychiatry","volume":"4 3","pages":"164-167"},"PeriodicalIF":0.0000,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000494700","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Neuropsychiatry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000494700","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/11/8 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 4

Abstract

Bipolar affective disorder (BPAD) is a chronic debilitating psychiatric illness seriously affecting the quality of patients' life. The available treatment is effective in about half of those suffering from the illness. The neurobiological basis of the disorder is not fully unraveled. With such lacunae, attempts have been made to decipher the underlying neuroimmunological process of the illness as is the case with other mental disorders. As a result, some inflammatory processes have been implicated in the etiology of BPAD, as described in this communication. Subsequently, the role of anti-inflammatory agents such as celecoxib was investigated by treating different phases of BPAD. Given the promising outcomes of several trials and reviews, celecoxib has gained momentum and has been recommended as an adjunctive treatment by some guidelines for treating resistant BPAD cases. This brief communication highlights some of the caveats in the randomized trials using celecoxib as an add-on treatment in bipolar mania specifically, which need to be addressed in future work.

查看原文本刊更多论文

在精神神经免疫学领域：塞来昔布作为双相躁狂附加疗法的作用。

双相情感障碍（BPAD）是一种严重影响患者生活质量的慢性衰弱性精神疾病。现有的治疗方法对大约一半的患者有效。这种疾病的神经生物学基础尚未完全阐明。有了这样的缺陷，人们试图解读这种疾病的潜在神经免疫过程，就像其他精神障碍一样。因此，正如本通讯所述，一些炎症过程与BPAD的病因有关。随后，通过治疗BPAD的不同阶段，研究了塞来昔布等抗炎药的作用。鉴于几项试验和综述的良好结果，塞来昔布获得了发展势头，并被一些治疗耐药BPAD病例的指南推荐为辅助治疗。这篇简短的通讯强调了使用塞来昔布作为双相躁狂附加治疗药物的随机试验中的一些注意事项，这些注意事项需要在未来的工作中解决。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Neuropsychiatry

自引率

0.00%

发文量